Clarius Group LLC Sells 12,072 Shares of Bristol Myers Squibb Company $BMY

Clarius Group LLC trimmed its stake in Bristol Myers Squibb Company (NYSE:BMY) by 49.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,537 shares of the biopharmaceutical company’s stock after selling 12,072 shares during the quarter. Clarius Group LLC’s holdings in Bristol Myers Squibb were worth $565,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Exchange Capital Management Inc. boosted its stake in Bristol Myers Squibb by 0.4% in the 2nd quarter. Exchange Capital Management Inc. now owns 54,893 shares of the biopharmaceutical company’s stock worth $2,541,000 after purchasing an additional 220 shares in the last quarter. Parsons Capital Management Inc. RI raised its holdings in Bristol Myers Squibb by 0.3% in the second quarter. Parsons Capital Management Inc. RI now owns 78,105 shares of the biopharmaceutical company’s stock worth $3,615,000 after buying an additional 224 shares during the last quarter. Richwood Investment Advisors LLC lifted its stake in shares of Bristol Myers Squibb by 1.7% in the second quarter. Richwood Investment Advisors LLC now owns 13,303 shares of the biopharmaceutical company’s stock worth $616,000 after buying an additional 225 shares in the last quarter. CBIZ Investment Advisory Services LLC grew its holdings in shares of Bristol Myers Squibb by 66.0% during the first quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 231 shares during the last quarter. Finally, Creative Financial Designs Inc. ADV increased its position in shares of Bristol Myers Squibb by 26.7% during the second quarter. Creative Financial Designs Inc. ADV now owns 1,123 shares of the biopharmaceutical company’s stock valued at $52,000 after acquiring an additional 237 shares in the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb Stock Up 0.9%

Bristol Myers Squibb stock opened at $54.68 on Tuesday. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $63.33. The stock has a fifty day moving average of $47.95 and a 200 day moving average of $47.18. The company has a debt-to-equity ratio of 2.39, a quick ratio of 1.17 and a current ratio of 1.27. The stock has a market cap of $111.32 billion, a PE ratio of 18.47, a price-to-earnings-growth ratio of 8.29 and a beta of 0.29.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The business had revenue of $12.22 billion during the quarter, compared to the consensus estimate of $11.75 billion. During the same period in the previous year, the company posted $1.80 EPS. The business’s quarterly revenue was up 2.8% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. As a group, sell-side analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd will be given a $0.63 dividend. The ex-dividend date is Friday, January 2nd. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 annualized dividend and a yield of 4.6%. Bristol Myers Squibb’s payout ratio is 83.78%.

Analyst Ratings Changes

BMY has been the topic of several analyst reports. Wells Fargo & Company upped their price objective on Bristol Myers Squibb from $53.00 to $55.00 and gave the company an “equal weight” rating in a research report on Wednesday, December 10th. Bank of America upgraded Bristol Myers Squibb from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $52.00 to $61.00 in a research note on Monday, December 15th. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Dbs Bank raised Bristol Myers Squibb to a “moderate buy” rating in a research report on Thursday, October 2nd. Finally, Morgan Stanley restated an “underweight” rating and set a $37.00 target price (up previously from $36.00) on shares of Bristol Myers Squibb in a research note on Friday, December 12th. Five research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Bristol Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $54.62.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.